KING OF PRUSSIA, Pa., March 27, 2014 (GLOBE NEWSWIRE) -- In December 2013, Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") announced there exists an agreement of sale executed on November 12, 2013 by its controlling shareholder for Company control to be passed on to a controlling shareholder group including Clover Capital and Parcae Capital Corp.
The Company is pleased to communicate key points which are important to its shareholders as it continues the due diligence process with Clover Capital and Parcae Capital. The Company is debt free and has liquid assets, including inventory, in excess of $1,000,000 on its balance sheet. Sales have grown from $23,000 in 2007 to $2,083,000 in 2012. Cumulatively, from 2007 inception through 2014 to date, sales are over $5,000,000.
The Company believes it has proven the concept its products can be sold in the network marketing space. The Company intends to improve its infrastructure by investing in added informational technology to support and better serve its network marketing business and members.
With the potential for new management and additional capital, the Company anticipates an ability to expand its network marketing presence. The Company plans on adding two new channels to its distribution, retail and infomercial. The Company also expects to complete rebranding of its line of product as well as adding a new product in the cancer nutritional supplementation market.
The Company is pleased with the progress to bring itself into full disclosure compliance with the Securities & Exchange Commission by working to complete a three year audit. The current intention is to file a Form 10 as a next step and then raise sufficient capital to enable immediate and future growth plans through an S-1, Regulation D or other appropriate offering.
About Emergent Health Corp.
Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. With licensed patented and patent pending nutritionally designed products, Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine as defined by the National Institute of Health.
This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.